No evidence seen for benefits of pancreatic cancer screening, according to study data.
A study conducted in a single institution sought to measure the impact including an oncology nurse navigator in the healthcare team has on patient treatment and outcomes.
A decision-analysis was used to determine which treatment of BR/LA PDAC was more efficacious and more cost-effective: neoadjuvant FOLFIRINOX vs surgery with GEM/CAPE vs surgery with gemcitabine.
In men, overweight and even higher normal weight is associated with an increased risk of future pancreatic cancer.
The goal of this study was to determine how molecular features change when PDAC progresses from a primary tumor to metastatic disease.
Predictive Role of Skin Rash in Advanced Pancreatic Cancer Patients Treated With Gemcitabine Plus Erlotinib: A Systematic Review and Meta-analysisNovember 02, 2018
[OncoTargets and Therapy] In this systematic review and meta-analysis, researchers sought to determine the predictive value of skin rash in patients with advanced pancreatic cancer treated with gemcitabine plus erlotinib.
In a comparison study with the seventh edition, updates in the eighth edition of the American Joint Committee on Cancer TNM staging resulted in a more equalized distribution across stages and modestly increased prognostic accuracy for nonmetastatic pancreatic ductal adenocarcinoma.
Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?September 14, 2018
[OncoTargets and Therapy] Although first-line therapy is effective, relapse is common; but many patients are good candidates for second-line therapy. This report reviews current published data on second-line therapies for advanced pancreatic cancer.
Investigators conducted a case-control study of 3030 pancreatic cancer patients in an attempt to confirm which genes might render patients susceptible to pancreatic cancer.
Seeking to determine if breath tests could be used to diagnose pancreatic cancer, researchers identified breath volatile organic compounds (VOCs) that may indicate presence of the disease.
FDA Fast Track designation was supported by data from a Phase 2 study reviewing pamrevlumab in combination with gemcitabine and nab-paclitaxel.
Those with pancreatic adenocarcinoma and a personal history of another cancer associated with hereditary breast and ovarian cancer or Lynch syndrome may be more likely to carry germline mutations.
Capecitabine and Oxaliplatin as First and Second Line Treatment for Locally Advanced and Metastatic Pancreatic Ductal AdenocarcinomaDecember 22, 2017
[Journal of Gastrointestinal Oncology] This research evaluates the use of capecitabine and oxaliplatin (CAPOX) for first or second-line treatment of locally advanced or metastatic PDAC.
Utilization and Trends in Palliative Therapy for Stage IV Pancreatic Adenocarcinoma Patients: A U.S. Population-based StudySeptember 29, 2017
[Journal of Gastrointestinal Oncology] This research examined patients who presented with metastatic pancreatic adenocarcinoma at diagnosis, and their patterns of palliative care utilization.
An association was found between low PNI/high CAR levels and poor outcomes in operable pancreatic ductal adenocarcinoma, even in patients who undergo curative resection.
By identifying incidence, prevalence, and risk factors for colorectal and pancreatic cancer in our communities, nurse navigators can develop screening and prevention programs to better serve these populations.
Precision Medicine Improves Pancreatic Cancer Treatment
Cisplatin plus standard-of-care gemcitabine/nab-paclitaxel improved tumor shrinkage in patients with metastatic pancreatic cancer, according to a study by the HonorHealth Research Institute and the Translational Genomics Research Institute.
Biopolymer codelivery of CAR T cells and stimulator of IFN genes directly to the surface of solid tumors more effectively reduced tumor size.
An investigation into whether onset or worsening of diabetes causes pancreatic cancer or vice versa was presented at the 2017 European Cancer Congress.
Use of Adjuvant gemcitabine plus capecitabine for patients with pancreatic cancer who have undergone tumor resection resulted in a modest increase short-term survival.
PDX1 appears to have distinct roles at different stages of pancreatic cancer development.
Seluminitinib in combination with an AKT inhibitor did not improve survival compared with modified FOLFOX in previously treated metastatic pancreatic cancer.
Favorable Perioperative Outcomes After Resection of Borderline Resectable Pancreatic Cancer Treated With Neoadjuvant Stereotactic Radiation and Chemotherapy Compared with Upfront Pancreatectomy for Resectable CancerAugust 25, 2016
[Journal of Gastrointestinal Oncology] This research examines outcomes related to the use of neoadjuvant multi-agent chemotherapy and stereotactic body radiation therapy (SBRT) in borderline resectable pancreatic cancer (BRPC) or locally advanced pancreatic cancer (LAPC) patients.
Research findings reveal the mechanism by which obesity increases inflammation and desmoplasia in the most frequent type of pancreatic cancer, using mouse models and human tissue samples.
Systematic Palliative Care Provides Greater Improvement in Quality of Life for Patients with Pancreatic CancerJuly 29, 2016
Quality of life is significantly improved for patients with pancreatic cancer when systematic palliative care is administered vs on-demand palliative care.
Metastatic capabilities of pancreatic cancer might arise before tumors even form. Metastasis and advanced stage of disease at diagnosis are attributed to low survival rates for pancreatic cancer.
Combining a laboratory ultrasound technique called sonoporation with the commercially available chemotherapy compound gemcitabine increases the porosity of pancreatic cells with microbubbles and helps get the drug into cancer cells.
Despite the increased risk, patients whose pancreatic cancer tumor has grown to encompass critical blood vessels can be candidates for surgery. Data on efforts to fine-tune a protocol for these patients were presented at the SSAT 57th Annual Meeting.
Adjuvant gemcitabine plus capecitabine significantly improved overall survival compared with gemcitabine monotherapy in patients with pancreatic ductal adenocarcinoma, according to results of the ESPAC-4 trial presented at the ASCO 2016 Annual Meeting.
Sign Up for Free e-newsletters
- Takeda to Collaborate With MSKCC on CAR-T Therapies for Multiple Myeloma
- Shorter Duration of Cryotherapy as Effective as Standard Therapy Prior to HSCT for Multiple Myeloma
- Sequential Immunotherapy, Targeted Therapy Linked to Cutaneous Adverse Events in Advanced Melanoma
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- 9/11 Responders May Have Higher Head and Neck Cancer Risk
- Oncology Nurse Navigation Facilitates Timely Treatment of Pancreatic Cancer
- Helping Patients Face the Challenge of Eating Healthy During Cancer Treatment
- Oncology Nurses Weigh In on Their Patient-Centered Communication Practices, Needs
- Substitute for Lidocaine
- CART cell therapy for prostate cancer: status and promise
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms
- A Review of Clinical Outcomes in Patients With Early-Stage Burkitt Lymphoma
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- USPSTF Still Recommends Against Pancreatic Cancer Screening
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|